A New Model for Predicting Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma

• Published in: Frontiers in oncology Vol. 10; p. 551255
• Main Authors: Peng, Liang, Mao, Yan-Ping, Huang, Cheng-Long, Guo, Rui, Ma, Jun, Wen, Wei-Ping, Tang, Ling-Long
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 25.09.2020
• Subjects: dosimetry parameters; hypothyroidism; intensity-modulated radiotherapy; nasopharyngeal carcinoma; Oncology; predicting model; intensity-modulated radiotherapy; nasopharyngeal carcinoma; predicting model; hypothyroidism; dosimetry parameters
• DOI: 10.3389/fonc.2020.551255
• ISSN: 2234-943X

To develop a model that can predict the risk of hypothyroidism (HT) after intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC), and to accordingly recommend dose constraints. NPC patients treated between 2011 and 2015 were retrospectively reviewed. HT was defined by an abnormally high level of thyrotropin. The dosimetry parameters V (percentage of thyroid volume receiving more than x Gy of radiation) and V (percentage of thyroid volume receiving >a Gy, while ≤b Gy radiation) were calculated. The primary endpoint was the development of HT within the first 2 years after IMRT. The least absolute shrinkage and selection operator and multivariate logistic regression were used to identify predictors of HT. A total of 545 patients were included in the analyses, with a median follow-up of 36 months. Of the 545 patients, 138 developed HT within 2 years, and the 2-year incidence of HT was 25.3%. In patients with thyroid volume >20 cm , the 2-year incidence of HT was 11.7% (16/137); in patients with thyroid volume ≤20 cm and V , ≤ 80%, the 2-year HT incidence was 19.9% (33/166); in patients with thyroid volume ≤20 cm and V , > 80%, the 2-year incidence of HT was 36.8% (89/242). Thyroid volume and V , could be reliable predictors of HT after IMRT for NPC. For patients with thyroid volume ≤20 cm , thyroid V , ≤ 80% might be a useful dose constraint to adopt during IMRT planning.